Needham & Company LLC Reiterates Buy Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They presently have a $28.00 target price on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 453.36% from the company’s […]
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They presently have a $28.00 target price on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 453.36% from the company’s […]
